Article Text

Download PDFPDF
IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS

Statistics from


  • Contributors SS, JM, CJK: study design. SS, CJK: writing the manuscript. SS, JRM, JMM-T, MMR, JM, JDT, MM, DD, SP, CJK: data collection. All co-authors: manuscript revision.

  • Funding The Mayo Clinic Foundation and its Center for Individualized Medicine have provided time to allow the authors to complete this work.

  • Disclaimer All the views expressed are those of the authors and not necessarily those of the Mayo Clinic Foundation.

  • Competing interests SJP: reports affiliation with Grifols, Alexion and Medimmune pharmaceuticals. He receives no personal compensation as all moneys are paid directly to Mayo Clinic; MM: reports receiving honorarium from Ackea related to TTR amyloidosis; DD Has received research support from Center of Multiple Sclerosis and Autoimmune Neurology, and Grifols pharmaceuticals. DD has consulted for UCB pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic; CJK reports receiving honorarium from Ackea related to TTR amyloidosis and Fabry disease. He has also been a consultant at Pfizer but received no personal compensation.

  • Patient consent for publication Not required.

  • Ethics approval Approval for this study was obtained by the Institutional Review Board at the Mayo Clinic and all patients provided written consent to participate.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.